The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia.
about
The effects of ketamine and risperidone on eye movement control in healthy volunteers.Ketamine for chronic pain: risks and benefits.Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.Glutamatergic model psychoses: prediction error, learning, and inferenceKetamine administration in healthy volunteers reproduces aberrant agency experiences associated with schizophrenia.Separable forms of reality monitoring supported by anterior prefrontal cortex.Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networksPredictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers.Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.What makes deeply encoded items memorable? Insights into the levels of processing framework from neuroimaging and neuromodulation.High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.Chronic administration of ketamine mimics the perturbed sense of body ownership associated with schizophrenia.
P2860
Q30437913-DA969350-F0C8-4A70-B9AE-239F7ED27397Q33582045-DE260AA1-42BF-421E-9623-DF0615084AC6Q34236634-E272A068-0CD8-4D26-8FD3-A33E6553F21DQ34661231-94312CA6-38A1-4F32-8337-D806147FBACDQ35130393-6062071D-BD12-43B9-9C5C-206B0E3A8403Q36539458-E623DD0B-2869-44D0-B375-085D3E56902CQ36609475-5C89C4F6-0B45-426D-9B43-DF5E5D71B4BAQ37220392-6BE5779A-AC4F-4715-A1DC-EBA0405C7B8FQ37338726-B9CB586A-64EB-40F5-AE6D-4160973E92CBQ37973222-FC3C5149-3419-4033-A5BB-DD4FD1A23A6BQ38105535-44821590-CE89-442D-AC3A-D7ECB4ADA9C4Q38218098-1D503684-F4DB-45A2-86F1-056C0D07C0F7Q41832396-17B08EDF-A832-4699-82DB-AA662BB9EC42Q47789466-EF9BCAC4-36B9-45CC-9C05-CCF904122C4B
P2860
The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The effects of a subpsychotic ...... ore symptoms of schizophrenia.
@en
The effects of a subpsychotic ...... ore symptoms of schizophrenia.
@nl
type
label
The effects of a subpsychotic ...... ore symptoms of schizophrenia.
@en
The effects of a subpsychotic ...... ore symptoms of schizophrenia.
@nl
prefLabel
The effects of a subpsychotic ...... ore symptoms of schizophrenia.
@en
The effects of a subpsychotic ...... ore symptoms of schizophrenia.
@nl
P2093
P2860
P50
P356
P1476
The effects of a subpsychotic ...... ore symptoms of schizophrenia.
@en
P2093
Chris O'loughlin
Danielle C Turner
Garry D Honey
P2860
P2888
P304
P356
10.1038/SJ.NPP.1300846
P407
P577
2006-02-01T00:00:00Z